MDXG Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of 14.73% compared to MiMedx Group, Inc.'s net margin of 27.14%. MiMedx Group, Inc.'s return on equity of 19.77% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

MiMedx Group, Inc. has a consensus price target of $12.20, signalling upside risk potential of 76.05%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 37.28%. Given that MiMedx Group, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe MiMedx Group, Inc. is more attractive than ADMA Biologics, Inc..

MiMedx Group, Inc. has a beta of 1.643, which suggesting that the stock is 64.306% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.

MiMedx Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MiMedx Group, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

MiMedx Group, Inc. quarterly revenues are $113.7M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. MiMedx Group, Inc.'s net income of $16.7M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, MiMedx Group, Inc.'s price-to-earnings ratio is 25.38x while ADMA Biologics, Inc.'s PE ratio is 23.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MiMedx Group, Inc. is 2.63x versus 9.99x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Aldeyra Therapeutics, Inc. has a net margin of 14.73% compared to MiMedx Group, Inc.'s net margin of --. MiMedx Group, Inc.'s return on equity of 19.77% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.

MiMedx Group, Inc. has a consensus price target of $12.20, signalling upside risk potential of 76.05%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 105.67%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than MiMedx Group, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than MiMedx Group, Inc..

MiMedx Group, Inc. has a beta of 1.643, which suggesting that the stock is 64.306% more volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.

MiMedx Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MiMedx Group, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.

MiMedx Group, Inc. quarterly revenues are $113.7M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. MiMedx Group, Inc.'s net income of $16.7M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, MiMedx Group, Inc.'s price-to-earnings ratio is 25.38x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MiMedx Group, Inc. is 2.63x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Praxis Precision Medicines, Inc. has a net margin of 14.73% compared to MiMedx Group, Inc.'s net margin of -786.27%. MiMedx Group, Inc.'s return on equity of 19.77% beat Praxis Precision Medicines, Inc.'s return on equity of -67.75%.

MiMedx Group, Inc. has a consensus price target of $12.20, signalling upside risk potential of 76.05%. On the other hand Praxis Precision Medicines, Inc. has an analysts' consensus of $331.60 which suggests that it could grow by 33.72%. Given that MiMedx Group, Inc. has higher upside potential than Praxis Precision Medicines, Inc., analysts believe MiMedx Group, Inc. is more attractive than Praxis Precision Medicines, Inc..

MiMedx Group, Inc. has a beta of 1.643, which suggesting that the stock is 64.306% more volatile than S&P 500. In comparison Praxis Precision Medicines, Inc. has a beta of 2.946, suggesting its more volatile than the S&P 500 by 194.607%.

MiMedx Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Praxis Precision Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MiMedx Group, Inc. pays -- of its earnings as a dividend. Praxis Precision Medicines, Inc. pays out -- of its earnings as a dividend.

MiMedx Group, Inc. quarterly revenues are $113.7M, which are larger than Praxis Precision Medicines, Inc. quarterly revenues of --. MiMedx Group, Inc.'s net income of $16.7M is higher than Praxis Precision Medicines, Inc.'s net income of -$73.9M. Notably, MiMedx Group, Inc.'s price-to-earnings ratio is 25.38x while Praxis Precision Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MiMedx Group, Inc. is 2.63x versus 701.87x for Praxis Precision Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 14.73% compared to MiMedx Group, Inc.'s net margin of -40.15%. MiMedx Group, Inc.'s return on equity of 19.77% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

MiMedx Group, Inc. has a consensus price target of $12.20, signalling upside risk potential of 76.05%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 118%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than MiMedx Group, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than MiMedx Group, Inc..

MiMedx Group, Inc. has a beta of 1.643, which suggesting that the stock is 64.306% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

MiMedx Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MiMedx Group, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MiMedx Group, Inc. quarterly revenues are $113.7M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. MiMedx Group, Inc.'s net income of $16.7M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, MiMedx Group, Inc.'s price-to-earnings ratio is 25.38x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MiMedx Group, Inc. is 2.63x versus 1.49x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.